Abstract
The past decade has witnessed the emergence of reliable and systematic gene discovery in ASDs. Over the past 5 years, dramatic progress has been made in identifying rare, large-effect mutations that contribute to approximately 20 percent of cases in the clinic. More recently, the first common alleles for ASD risk have also been identified, contributing very small individual effects but across a greater percentage of the population. These molecular clues offer a foothold into the pathophysiology of ASD and, consequently, offer a number of potential paths from the gene to therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
